Navigation Links
Brookstone Pharmaceuticals Appoints New Corporate Position
Date:7/30/2009

ALPHARETTA, Ga., July 30 /PRNewswire/ -- Brookstone Pharmaceuticals, LLC, a specialty pharmaceutical company, recently announced the appointment of Philip Vogt as Executive Vice President, Sales and Marketing.

Vogt brings more than thirty years of pharmaceutical experience and will lead the sales and marketing effort within Brookstone. Prior to this role, Vogt served as President of Ethex Corporation in St. Louis, MO. Vogt developed initiatives to expand presence in new therapeutic markets and introduced proactive, customer-focused practices to deliver value and enhance relationships with trading partners. Other positions held include: Vice President, Marketing and National Sales Manager. Vogt received a B.S. in Business Administration from Louisiana State University.

"The appointment of Philip demonstrates our continued commitment to a growth strategy planned around excellence and strength. We look forward to developing Brookstone as a company of distinction, built with the highest caliber of integrity and talent in the market," said Mark Pugh, CEO Brookstone Pharmaceuticals.


'/>"/>
SOURCE Brookstone Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Colo. , Jan. 23, 2015  Array BioPharma Inc. ... has reached a definitive agreement with Novartis Pharma AG ... inhibitor currently in Phase 3 development.  This agreement is conditional ... GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected ...
(Date:1/22/2015)... 22, 2015 Eckert & Ziegler Vitalea ... (AMS) services to the pharmaceutical and biotech industry, has ... company in the position of Director of Science & ... and valuable experience in drug metabolism and bioanalysis to ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... DALLAS, February 1, 2012 The report ... -   Global Trends, Opportunities & Forecasts (2011   - ... and studies the major market drivers, restraints, and opportunities in ... Browse market data tables and in-depth TOC ...
... 2012 New Report Added in ... Global Markets The report provides ... DDS and future opportunities (2011-2021).  Persons with a financial ... to learn how advances in nanotechnology research and development ...
... in Dayton, Ohio, has experimentally confirmed a theory by ... of interesting properties about nanotube growth: That the chirality ... and that armchair nanotubes should grow the fastest. ... the mysteries inherent in what Yakobson calls the "DNA ...
Cached Biology Technology:MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 2MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 2ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 4Rice professor's nanotube theory confirmed 2Rice professor's nanotube theory confirmed 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
... (11/12/2012) If you,ve eaten fish, gone for a boat ride or ... is a valuable commodity. But just how valuable? That,s always been ... the worth of clean water against societal needs that compromise it, ... Now, however, their ability to do so has been greatly enhanced ...
... have estimated that there are 1.7 million species of ... continue to be discovered. Unfortunately, as new species are ... decrease in biodiversity. The more diversity there is in ... Hence, biodiversity is key to ecosystem resilience. Disease, ...
Cached Biology News:Plan to turn farm waste into paper earns students $15,000 2Study offers new tool for incorporating water impacts into policy decisions 2Persistence or extinction: Through a mathematical lens 2Persistence or extinction: Through a mathematical lens 3